Export
Model List of Essential Medicines
Found 1097 recommendations for 557 medicines and 44 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
Abacavir General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 60 mg tablet (dispersible, scored) (as sulfate); 300 mg tablet (as sulfate)
-
Abacavir + lamivudine General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
-
Abiraterone General information
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Acetazolamide General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Oral > Solid: 250 mg
Indications -
Acetic acid General information
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 2% in alcohol
Indications -
Acetylcysteine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%
-
Acetylsalicylic acid General information
SectionAntimigraine medicines > For treatment of acute attack- Oral > Solid: 300 to 500 mg
IndicationsSectionAnti-platelet medicines- Oral > Solid: 100 mg
IndicationsSectionJuvenile joint diseases- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
Indications -
Aciclovir General information
SectionAntiherpes medicines- Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
IndicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 3% w/w
Indications -
Activated charcoal General information
SectionAntidotes and other substances used in poisonings > Non-specific- Oral > Other: powder
-
Adalimumab General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL
-
Afatinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Albendazole General information
SectionAntifilarials- Oral > Solid: 400 mg tablet (chewable)
IndicationsSectionIntestinal anthelminthics- Oral > Solid: 400 mg tablet (chewable)
-
Alcohol based hand rub General information
SectionDisinfectants- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
Indications -
All-trans retinoic acid General information
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol General information
SectionSupportive medicines- Oral > Solid: 100 mg tablet; 300 mg tablet
IndicationsSectionMedicines used to treat gout- Oral > Solid: 100 mg
Indications -
Alteplase General information
SectionThrombolytic medicines- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
Indications -
Amidotrizoate General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
Indications -
Amikacin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsFirst choice
Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)Second choice
co-prescribed with cloxacillin Sepsis without septic shockSectionAntituberculosis medicines- Parenteral > General injections > unspecified: 1 g in vial powder for injection (as sulfate); 500 mg in vial powder for injection (as sulfate); 100 mg in vial powder for injection (as sulfate)
Indications -
Amiloride General information
-
Amiodarone General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Amitriptyline General information
SectionMedicines used in depressive disorders- Oral > Solid: 25 mg; 75 mg
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Solid: 25 mg; 10 mg; 75 mg
Indications -
Amlodipine General information
SectionAntihypertensive medicines- Oral > Solid: 5 mg (as maleate, mesylate or besylate)
Indications -
Amodiaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
Indications -
Amodiaquine + sulfadoxine + pyrimethamine General information
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
Indications -
Amoxicillin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
IndicationsFirst choice
Periapical abscess without sinus Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute otitis media Infectious cystitis Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Acute sinusitis co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shockSecond choice
Bacterial meningitis -
Amoxicillin + clavulanic acid General information
SectionAccess group antibiotics- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
- Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
IndicationsFirst choice
Peritonitis (mild-moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Other specified pneumonia (Hospital-acquired pneumonia) Neutropenia (low-risk) Peritoneal abscess (mild-moderate) Acute sinusitis Infectious cystitis Bacterial cellulitis, erysipelas and lymphangitis Chronic obstructive pulmonary disease with acute exacerbationSectionAntituberculosis medicines- Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
- Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Indications -
Amphotericin b General information
SectionAntileishmaniasis medicines- Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
IndicationsSectionAntifungal medicines- Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
-
Ampicillin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
IndicationsFirst choice
co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shockSecond choice
Bacterial meningitis -
Anastrozole General information
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Anti-d immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial
-
Anti-rabies immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial
Indications -
Anti-tetanus immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IM: 500 IU in vial
Indications -
Antivenom immunoglobulin General information
SectionImmunologicals > Sera and immunoglobulins- Parenteral > General injections > IV:
-
Apixaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism -
Aprepitant General information
SectionAntiemetic medicines- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid: 80 mg; 125 mg; 165 mg
Indications -
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
-
Artemether General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection)
Indications -
Artemether + lumefantrine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
Indications -
Artesunate General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
- Oral > Solid: 50 mg tablet
- Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
Indications -
Artesunate + amodiaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
Indications -
Artesunate + mefloquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
Indications -
Artesunate + pyronaridine tetraphosphate General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
-
Ascorbic acid General information
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Atazanavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
-
Atazanavir + ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
-
Atenolol General information
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertension -
Atorvastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Atracurium General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 10 mg per mL (besylate)
-
Atropine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
-
Azathioprine General information
SectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 50 mg
IndicationsSectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
- Oral > Solid: 50 mg
-
Azithromycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
IndicationsSectionWatch group antibiotics- Oral > Liquid: 200 mg per 5 mL oral liquid
- Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
IndicationsFirst choice
Typhoid fever Cholera Paratyphoid Fever Chlamydia trachomatis co-prescribed with ceftriaxone Gonococcal infectionSecond choice
Gastroenteritis and colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infectionOther indications -
Barium sulfate General information
SectionDiagnostic agents > Radiocontrast media- Oral > Liquid: Aqueous suspension
Indications -
Bcg vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Beclometasone General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
Indications -
Bedaquiline General information
SectionAntituberculosis medicines- Oral > Solid: 100 mg tablet
Indications -
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Benzathine benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
-
Benznidazole General information
SectionAmerican trypanosomiasis- Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet
Indications -
Benzoyl peroxide General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%
Indications -
Benzyl benzoate General information
SectionDermatological medicines (topical) > Scabicides and pediculicides- Local > Topical > Lotion: 25%
Indications -
Benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
IndicationsFirst choice
Congenital syphilis [children] Syphilis co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shockSecond choice
Bacterial meningitis -
Betamethasone General information
SectionDermatological medicines (topical) > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)
-
Bevacizumab General information
SectionOphthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications -
Bicalutamide General information
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Biperiden General information
SectionAntiparkinsonism medicines- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)
Indications -
Bisoprolol General information
SectionAntianginal medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionMedicines used in heart failure- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntiarrhythmic medicines- Oral > Solid: 1.25 mg; 5 mg
Indications -
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
-
Bortezomib General information
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Budesonide General information
SectionEar, nose and throat medicines [c]- Local > Nasal > Spray: 100 µg per dose
IndicationsSectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
Indications -
Budesonide + formoterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
Indications -
Bupivacaine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
Indications -
Caffeine citrate General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
Indications -
Calamine General information
SectionDermatological medicines (topical) > Anti-inflammatory and antipruritic medicines- Local > Topical > Lotion:
Indications -
Calcium General information
SectionVitamins and minerals- Oral > Solid: 500 mg (elemental calcium)
Indications -
Calcium folinate General information
SectionCytotoxic medicines- Oral > Solid: 15 mg tablet; 5 mg tablet; 25 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
-
Calcium gluconate General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
IndicationsSectionVitamins and minerals- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
Indications -
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid: 150 mg tablet; 500 mg tablet
-
Carbamazepine General information
SectionAnticonvulsants/antiepileptics- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)
IndicationsSectionMedicines used in bipolar disorders- Oral > Solid: 100 mg scored; 200 mg scored
Indications -
Carbetocin General information
SectionUterotonics- Parenteral > General injections > IV: 100 µg per mL (heat stable)
Indications -
Carbimazole General information
SectionThyroid hormones and antithyroid medicinesIndicationsTherapeutic equivalent to methimazole for Thyrotoxicosis -
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
-
Carvedilol General information
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol for Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol for Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol for Cardiac arrhythmia -
Cefalexin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate)
-
Cefazolin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
IndicationsFirst choice
Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures -
Cefixime General information
SectionWatch group antibiotics- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
IndicationsSecond choice
Gastroenteritis and colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection -
Cefotaxime General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)
IndicationsFirst choice
Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) -
Ceftazidime General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
-
Ceftazidime + avibactam General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
-
Ceftriaxone General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
IndicationsFirst choice
Bacterial meningitis Other specified pneumonia (Hospital-acquired pneumonia) Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid Fever co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) -
Cefuroxime General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
-
Certolizumab pegol General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Chloramphenicol General information
SectionAccess group antibiotics- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
- Oral > Liquid: 150 mg per 5 mL (as palmitate)
- Oral > Solid: 250 mg capsule
-
Chlorhexidine General information
SectionMedicines administered to the neonate [c]- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
IndicationsSectionAntiseptics- Local > Topical > Solution: 5% (digluconate) for dilution
Indications -
Chlorine base compound General information
SectionDisinfectants- Local > Topical > Powder: 0.1% available chlorine for solution
Indications -
Chloroquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)
SectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
Indications -
Chloroxylenol General information
SectionDisinfectants- Local > Topical > Solution: 4.8%
Indications -
Chlorpromazine General information
SectionMedicines used in psychotic disorders- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
-
Cholera vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Ciclosporin General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Solid: 25 mg
-
Ciprofloxacin General information
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 0.3% (as hydrochloride)
IndicationsSectionWatch group antibiotics- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid: 250 mg (as hydrochloride)
IndicationsFirst choice
Typhoid fever Inflammatory and other diseases of prostate (mild to moderate) Paratyphoid Fever Acute pyelonephritis (mild to moderate) Neutropenia (low-risk) Gastroenteritis and colitis without specification of infectious agentSecond choice
Cholera co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate) -
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL
IndicationsOther specified malignant neoplasms of the ovary Osteosarcoma of bone and articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oropharynx Malignant neoplasms of cervix uteri Malignant neoplasms of nasopharynx -
Clarithromycin General information
SectionWatch group antibiotics- Oral > Solid: 500 mg
- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
IndicationsFirst choice
co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)Second choice
Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)Other indications -
Clindamycin General information
SectionAccess group antibiotics- Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride) capsule
- Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
-
Clofazimine General information
SectionAntituberculosis medicines- Oral > Solid: 100 mg; 50 mg
IndicationsSectionAntileprosy medicines- Oral > Solid: 100 mg; 50 mg
Indications -
Clomifene General information
SectionOvulation inducers- Oral > Solid: 50 mg (citrate)
-
Clomipramine General information
SectionMedicines used for obsessive compulsive disorders- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Clopidogrel General information
SectionAnti-platelet medicines- Oral > Solid: 75 mg; 300 mg
-
Clotrimazole General information
SectionAntifungal medicines- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
Indications -
Cloxacillin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
- Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
IndicationsFirst choice
Osteomyelitis or osteitis Bacterial cellulitis, erysipelas and lymphangitis Bacterial infection of jointSecond choice
co-prescribed with amikacin Sepsis without septic shock -
Clozapine General information
SectionMedicines used in psychotic disorders- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
-
Coagulation factor ix complex General information
SectionBlood coagulation factors- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
-
Coagulation factor viii General information
SectionBlood coagulation factors- Parenteral > General injections > IV: 500 IU in vial powder for injection
Indications -
Coal tar General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
Indications -
Codeine General information
SectionOpioid analgesics- Oral > Solid: 30 mg tablet (codeine phosphate)
Indications -
Colecalciferol General information
SectionVitamins and minerals- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU
IndicationsCalcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency -
Colistin General information
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
-
Compound sodium lactate solution General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: injectable solution
-
Condoms General information
SectionBarrier methods- -
-
Copper-containing intrauterine device General information
SectionIntrauterine devices- -
-
Cyclizine General information
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 50 mg tablet
- Parenteral > General injections > unspecified: 50 mg per mL
Indications -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet
IndicationsMalignant trophoblastic neoplasms of placenta Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Other specified malignant neoplasms of breast Lymphoid leukaemia, NOS Chronic lymphocytic leukaemia or small lymphocytic lymphoma Malignant neoplasms of breast Rhabdomyosarcoma primary site Hodgkin lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Diffuse large B-cell lymphomas -
Cycloserine General information
SectionAntituberculosis medicines- Oral > Solid: 250 mg; 125 mg
Indications -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
-
Dabigatran General information
SectionMedicines affecting coagulation- Oral > Solid: 110 mg; 150 mg
-
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection
Indications -
Daclatasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
IndicationsChronic hepatitis C Therapeutic equivalent to glecaprevir + pibrentasvir for Chronic hepatitis C Therapeutic equivalent to sofosbuvir + velpatasvir for Chronic hepatitis C Therapeutic equivalent to sofosbuvir for Chronic hepatitis C -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dalteparin General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism -
Dapsone General information
SectionAntileprosy medicines- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
Indications -
Darbepoetin alfa General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia of chronic disease -
Darunavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
-
Dasabuvir General information
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 250 mg tablet
Indications -
Dasatinib General information
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
Indications -
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
-
Deferoxamine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
SectionOther medicines for haemoglobinopathies- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
-
Delamanid General information
SectionAntituberculosis medicines- Oral > Solid: 50 mg tablet
Indications -
Dengue vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Desmopressin General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 10 µg per dose (acetate)
Indications -
Dexamethasone General information
SectionOther medicines administered to the mother- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
SectionAntiemetic medicines- Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
- Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
Indications -
Dextran 70 General information
SectionPlasma substitutes- Parenteral > General injections > IV: 6% injectable solution
Indications -
Diaphragms General information
SectionBarrier methods- -
-
Diazepam General information
SectionAnticonvulsants/antiepileptics- Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
- Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 5 mg (scored); 2 mg (scored)
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 5 mg; 10 mg
- Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg
- Parenteral > General injections > unspecified: 5 mg per mL
Indications -
Diazoxide General information
SectionMedicines for hypoglycaemia- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg
-
Diethylcarbamazine General information
SectionAntifilarials- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
Indications -
Digoxin General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg
IndicationsSectionMedicines used in heart failure- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg
Indications -
Dihydroartemisinin + piperaquine phosphate General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
Indications -
Diloxanide General information
SectionAntiamoebic and antigiardiasis medicines- Oral > Solid: 500 mg (furoate)
Indications -
Dimercaprol General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
-
Diphtheria antitoxin General information
SectionImmunologicals > Sera and immunoglobulins- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
Indications -
Diphtheria vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Docusate sodium General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 50 mg per 5 mL oral liquid
- Oral > Solid: 100 mg capsule
Indications -
Dolutegravir General information
SectionAntiretrovirals > Integrase inhibitors- Oral > Solid: 50 mg tablet
-
Dolutegravir + lamivudine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Dopamine General information
SectionMedicines used in heart failure- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
Indications -
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
IndicationsMalignant neoplasms of breast Hodgkin lymphoma Other specified malignant neoplasms of breast Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, NOS Plasma cell myeloma Kaposi sarcoma of unspecified primary site Diffuse large B-cell lymphomas -
Doxycycline General information
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
- Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Solid: 100 mg (as hyclate)
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg (hydrochloride or hyclate)
IndicationsSectionAntimalarial medicines > For curative treatment- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
Indications -
Edoxaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism -
Efavirenz General information
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Solid: 600 mg tablet; 200 mg scored tablet
-
Efavirenz + emtricitabine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Efavirenz + lamivudine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
-
Eflornithine General information
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride)
Indications -
Emtricitabine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Enalapril General information
SectionAntihypertensive medicines- Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
IndicationsSectionMedicines used in heart failure- Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
Indications -
Enoxaparin General information
SectionMedicines affecting coagulation- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
Indications -
Entecavir General information
SectionMedicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg
Indications -
Ephedrine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
Indications -
Epinephrine General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
IndicationsSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
IndicationsSectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
Indications -
Epoetin alfa General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia of chronic disease -
Epoetin beta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia of chronic disease -
Epoetin theta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia of chronic disease -
Ergocalciferol General information
SectionVitamins and minerals- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)
Indications -
Ergometrine General information
SectionUterotonics- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
Indications -
Erlotinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Erythromycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 0.5%
-
Erythropoiesis-stimulating agents General information
SectionAntianaemia medicines- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
Indications -
Estradiol cypionate + medroxyprogesterone acetate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 5 mg + 25 mg
-
Etanercept General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Ethambutol General information
SectionAntituberculosis medicines- Oral > Liquid: 25 mg per mL
- Oral > Solid: 100 to 400 mg tablet (hydrochloride); 100 mg dispersible tablet
Indications -
Ethambutol + isoniazid + pyrazinamide + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
Indications -
Ethambutol + isoniazid + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 150 mg tablet
Indications -
Ethanol General information
SectionAntiseptics- Local > Topical > Solution: 70% (denatured)
Indications -
Ethinylestradiol + levonorgestrel General information
SectionOral hormonal contraceptives- Oral > Solid: 30 µg + 150 µg
Indications -
Ethinylestradiol + norethisterone General information
SectionOral hormonal contraceptives- Oral > Solid: 35 µg + 1 mg
Indications -
Ethionamide General information
SectionAntituberculosis medicines- Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible)
Indications -
Ethosuximide General information
SectionAnticonvulsants/antiepileptics- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg
Indications -
Etonogestrel-releasing implant General information
SectionImplantable contraceptives- Implant > Subdermal: 68 mg single rod
-
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsOther specified malignant neoplasms of bronchus or lung Malignant trophoblastic neoplasms of placenta Germ cell tumour of testis Hodgkin lymphoma Other specified malignant neoplasms of the ovary Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, NOS Retinoblastoma -
Fentanyl General information
SectionOpioid analgesics- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Indications -
Ferrous salt General information
SectionAntianaemia medicines- Oral > Liquid: 25 mg per mL iron (as sulfate)
- Oral > Solid: 60 mg iron
Indications -
Ferrous salt + folic acid General information
SectionAntianaemia medicines- Oral > Solid: 60 mg iron + 400 µg tablet
-
Fexinidazole General information
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Oral > Solid: 600 mg
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid: 600 mg
Indications -
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fluconazole General information
SectionAntifungal medicines- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 50 mg capsule
Indications -
Flucytosine General information
SectionAntifungal medicines- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule
Indications -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fludrocortisone General information
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 100 µg (acetate)
Indications -
Fluorescein General information
SectionDiagnostic agents > Ophthalmic medicines- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
Indications -
Fluorouracil General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Ointment: 5%
Indications -
Fluoxetine General information
SectionMedicines used in depressive disorders- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Solid: 20 mg (as hydrochloride)
Indications -
Fluphenazine General information
SectionMedicines used in psychotic disorders- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
Indications -
Fluvastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Folic acid General information
SectionAntianaemia medicines- Oral > Solid: 1 mg tablet; 5 mg tablet
- Oral > Solid: 400 µg
-
Fomepizole General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
-
Fosfomycin General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
-
Fresh-frozen plasma General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Furosemide General information
SectionDiuretics- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
- Oral > Liquid: 20 mg per 5 mL
- Oral > Solid: 40 mg; 10 mg; 20 mg
IndicationsSectionMedicines used in heart failure- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
- Oral > Liquid: 20 mg per 5 mL
- Oral > Solid: 40 mg
Indications -
Gefitinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Gentamicin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
IndicationsFirst choice
co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shockSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
Indications -
Glecaprevir + pibrentasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 100 mg + 40 mg tablet
IndicationsTherapeutic equivalent to daclatasvir for Chronic hepatitis C Chronic hepatitis C Therapeutic equivalent to sofosbuvir + velpatasvir for Chronic hepatitis C Therapeutic equivalent to sofosbuvir for Chronic hepatitis C -
Gliclazide General information
SectionOral hypoglycaemic agents- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
Indications -
Glucagon General information
SectionMedicines for hypoglycaemia- Parenteral > General injections > unspecified: 1 mg per mL
Indications -
Glucose General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
- Parenteral > General injections > IV: 50% hypertonic
-
Glucose + sodium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
-
Glutaral General information
SectionDisinfectants- Local > Topical > Solution: 2%
Indications -
Glyceryl trinitrate General information
SectionAntianginal medicines- Oral > Solid: 500 µg sublingual tablet
Indications -
Golimumab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Griseofulvin General information
SectionAntifungal medicines- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg
Indications -
Haemophilus influenzae type b vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Haloperidol General information
SectionMedicines used in psychotic disorders- Parenteral > General injections > IM: 5 mg per mL in ampoule
- Oral > Liquid: 2 mg per mL
- Oral > Solid: 2 mg; 0.5 mg; 5 mg
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Oral > Solid: 0.5 mg; 2 mg; 5 mg
- Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
Indications -
Halothane General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Heparin sodium General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
-
Hepatitis a vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Hepatitis b vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Hpv vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Hydralazine General information
SectionAntihypertensive medicines- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Hydrochlorothiazide General information
SectionMedicines used in heart failure- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg
IndicationsSectionDiuretics- Oral > Solid: 25 mg
IndicationsSectionAntihypertensive medicines- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg
Indications -
Hydrocortisone General information
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
IndicationsSectionAdrenal hormones and synthetic substitutes- Oral > Solid: 5 mg; 10 mg; 20 mg
IndicationsSectionAnti-inflammatory medicines- Local > Rectal > Suppository: 25 mg (acetate)
- Local > Rectal > Retention enema:
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
IndicationsSectionDermatological medicines (topical) > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 1% (acetate)
- Local > Topical > Ointment: 1% (acetate)
-
Hydromorphone General information
-
Hydroxocobalamin General information
SectionAntianaemia medicines- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
-
Hydroxycarbamide General information
SectionOther medicines for haemoglobinopathies- Oral > Solid: 200 mg; 500 mg; 1 g
SectionCytotoxic medicines- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Indications -
Hydroxychloroquine General information
SectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 200 mg (as sulfate)
Indications -
Hyoscine butylbromide General information
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > unspecified: 20 mg per mL injection
Indications -
Hyoscine hydrobromide General information
SectionMedicines for other common symptoms in palliative care- Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
- Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
Indications -
Ibuprofen General information
SectionAntimigraine medicines > For treatment of acute attack- Oral > Solid: 200 mg; 400 mg
IndicationsSectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 5 mg per mL
IndicationsSectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg; 400 mg; 600 mg
Indications -
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
-
Imatinib General information
SectionTargeted therapies- Oral > Solid: 100 mg tablet; 400 mg tablet
-
Indometacin General information
SectionMedicines administered to the neonate [c]IndicationsTherapeutic equivalent to ibuprofen for Patent arterial duct -
Infliximab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis -
Influenza vaccine (seasonal) General information
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Insulin General information
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)
Indications -
Intermediate-acting insulin General information
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin
Indications -
Intraperitoneal dialysis solution General information
SectionPeritoneal dialysis solution- parenteral solution
Indications -
Iodine General information
SectionVitamins and minerals- Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
- Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
- Oral > Solid: 190 mg
Indications -
Iohexol General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
Indications -
Ipratropium bromide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 20 µg per dose
Indications -
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
Indications -
Isoflurane General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Isoniazid General information
SectionAntituberculosis medicines- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 100 to 300 mg tablet; 50 mg tablet (scored); 100 mg tablet (dispersible)
Indications -
Isoniazid + pyrazinamide + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible); 75 mg + 400 mg + 150 mg tablet
Indications -
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
SectionMedicines for prevention of HIV-related opportunistic infections- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
Indications -
Isoniazid + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
Indications -
Isosorbide dinitrate General information
SectionAntianginal medicines- Oral > Solid: 5 mg sublingual tablet
Indications -
Itraconazole General information
SectionAntifungal medicines- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg
-
Ivermectin General information
SectionIntestinal anthelminthics- Oral > Solid: 3 mg tablet (scored)
SectionAntifilarials- Oral > Solid: 3 mg tablet (scored)
IndicationsSectionMedicines for ectoparasitic infections- Oral > Solid: 3 mg tablet (scored)
Indications -
Japanese encephalitis vaccine General information
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Ketamine General information
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
Indications -
Lactulose General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
Indications -
Lamivudine General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet
-
Lamivudine + nevirapine + zidovudine General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
-
Lamivudine + zidovudine General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
-
Lamotrigine General information
SectionAnticonvulsants/antiepileptics- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
Indications -
Latanoprost General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
Indications -
Ledipasvir + sofosbuvir General information
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 90 mg + 400 mg tablet
Indications -
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Leuprorelin General information
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Levamisole General information
SectionIntestinal anthelminthics- Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)
Indications -
Levodopa + carbidopa General information
SectionAntiparkinsonism medicines- Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
Indications -
Levofloxacin General information
SectionAntituberculosis medicines- Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
Indications -
Levonorgestrel General information
SectionIntrauterine devices- Intrauterine system with reservoir containing 52 mg of levonorgestrel.
SectionOral hormonal contraceptives- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg
-
Levonorgestrel-releasing implant General information
SectionImplantable contraceptives- Implant > Subdermal: 75 mg per rod (two-rods)
-
Levothyroxine General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
Indications -
Lidocaine General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
IndicationsSectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)
Indications -
Lidocaine + epinephrine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
Indications -
Linezolid General information
SectionAntituberculosis medicines- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet; 150 mg tablet (dispersible)
IndicationsSectionReserve group antibiotics- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 400 mg tablet; 600 mg tablet
-
Lisinopril + amlodipine General information
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
Indications -
Lisinopril + hydrochlorothiazide General information
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
Indications -
Lithium carbonate General information
SectionMedicines used in bipolar disorders- Oral > Solid: 300 mg
Indications -
Loperamide General information
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 2 mg solid oral dosage form
Indications -
Lopinavir + ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Liquid: 400 mg + 100 mg per 5 mL
- Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
-
Loratadine General information
SectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 1 mg per mL oral liquid
- Oral > Solid: 10 mg tablet
-
Lorazepam General information
SectionAnticonvulsants/antiepileptics- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
Indications -
Losartan General information
SectionAntihypertensive medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
IndicationsSectionMedicines used in heart failure- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
Indications -
Lovastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Lugol's solution General information
SectionThyroid hormones and antithyroid medicines- Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
Indications -
Magnesium sulfate General information
SectionAnticonvulsants/antiepileptics- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
Indications -
Mannitol General information
SectionDiuretics- Parenteral > General injections > IV: 10% solution; 20% solution
Indications -
Measles vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mebendazole General information
SectionIntestinal anthelminthics- Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)
Indications -
Medroxyprogesterone acetate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
SectionProgestogens- Oral > Solid: 5 mg
Indications -
Mefloquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 250 mg tablet (hydrochloride)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Solid: 250 mg tablet (hydrochloride)
Indications -
Meglumine antimoniate General information
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony
-
Meglumine iotroxate General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
Indications -
Melarsoprol General information
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
Indications -
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Meningococcal meningitis vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg tablet
-
Meropenem General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
IndicationsSectionAntituberculosis medicines- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
Indications -
Meropenem + vaborbactam General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
-
Mesalazine General information
SectionAnti-inflammatory medicinesIndicationsTherapeutic equivalent to sulfasalazine for Ulcerative colitis Therapeutic equivalent to sulfasalazine for Crohn disease site -
Mesna General information
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
-
Metformin General information
SectionOral hypoglycaemic agents- Oral > Solid: 500 mg (hydrochloride)
Indications -
Methadone General information
SectionMedicines for disorders due to psychoactive substance use- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
IndicationsSectionOpioid analgesics- Oral > Liquid: 5 mg per 5 mL (as hydrochloride); 10 mg per 5 mL (as hydrochloride); 5 mg per mL concentrate for oral liquid (as hydrochloride); 10 mg per mL concentrate for oral liquid (as hydrochloride)
- Oral > Solid: 5 mg (as hydrochloride); 10 mg (as hydrochloride)
Indications -
Methimazole General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 5 mg; 10 mg; 20 mg
Indications -
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
SectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 2.5 mg (as sodium salt)
Indications -
Methoxy polyethylene glycol-epoetin beta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia of chronic disease -
Methyldopa General information
SectionAntihypertensive medicines- Oral > Solid: 250 mg
Indications -
Methylprednisolone General information
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
Indications -
Methylthioninium chloride General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
Indications -
Metoclopramide General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
Indications -
Metoprolol General information
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol for Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol for Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol for Cardiac arrhythmia -
Metronidazole General information
SectionAccess group antibiotics- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
IndicationsFirst choice
Trichomoniasis Enterocolitis due to Clostridium difficile co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe)Second choice
co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate)SectionAntiamoebic and antigiardiasis medicines- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Oral > Solid: 200 to 500 mg tablet
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
Indications -
Miconazole General information
SectionDermatological medicines (topical) > Antifungal medicines- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)
Indications -
Midazolam General information
SectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 1 mg per mL
- Oral > Liquid: 2 mg per mL
- Oral > Solid: 15 mg tablet; 7.5 mg tablet
IndicationsSectionAnticonvulsants/antiepileptics- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL oral liquid
- Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
- Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
Indications -
Mifepristone - misoprostol General information
SectionUterotonics- Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
-
Miltefosine General information
SectionAntileishmaniasis medicines- Oral > Solid: 10 mg; 50 mg
-
Misoprostol General information
SectionUterotonics- Oral > Solid: 200 µg
- Local > Vaginal > tablet: 25 µg
-
Morphine General information
SectionOpioid analgesics- Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
- Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
- Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
- Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
Indications -
Moxifloxacin General information
SectionAntituberculosis medicines- Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
Indications -
Multiple micronutrient powder General information
SectionVitamins and minerals- Oral > Other:
Indications -
Mumps vaccine General information
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mupirocin General information
SectionDermatological medicines (topical) > Anti-infective medicines- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%
Indications -
Nadroparin General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism -
Naloxone General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
-
Natamycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Suspension: 5% eye drops
Indications -
Neostigmine General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Oral > Solid: 15 mg (neostigmine bromide)
- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Indications -
Nevirapine General information
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL oral solution
- Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
-
Niclosamide General information
SectionIntestinal anthelminthics- Oral > Solid: 500 mg tablet (chewable)
-
Nicotinamide General information
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Nicotine replacement therapy General information
SectionMedicines for disorders due to psychoactive substance use- Oral > Other: 2 mg chewing gum; 4 mg chewing gum
- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
Indications -
Nifedipine General information
SectionAntioxytocics (tocolytics)- Oral > Solid: 10 mg (immediate-release)
Indications -
Nifurtimox General information
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid: 120 mg
IndicationsSectionAmerican trypanosomiasis- Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet
Indications -
Nilotinib General information
SectionTargeted therapies- Oral > Solid: 150 mg capsule; 200 mg capsule
Indications -
Nitrofurantoin General information
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid: 100 mg tablet
-
Nitrous oxide General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Norethisterone General information
SectionProgestogensIndicationsTherapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle -
Norethisterone enantate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
-
Normal immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution
-
Nystatin General information
SectionAntifungal medicines- Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL
- Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet
- Local > Topical > Other: 100000 IU pessary
Indications -
Ofloxacin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3%
Indications -
Ombitasvir + paritaprevir + ritonavir General information
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
Indications -
Omeprazole General information
SectionAntiulcer medicines- Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
- Oral > Solid: 10 mg; 20 mg; 40 mg
- Parenteral > General injections > IV: 40 mg in vial
-
Ondansetron General information
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
IndicationsSectionAntiemetic medicines- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
Indications -
Oral rehydration salts General information
SectionOral rehydration- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
-
Oral rehydration salts - zinc sulfate General information
SectionMedicines used in diarrhoea- Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
Indications -
Oseltamivir General information
SectionOther antivirals- Oral > Liquid: 12 mg per mL powder for oral liquid
- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
-
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Oxamniquine General information
SectionAntischistosomals and other antitrematode medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg capsule
Indications -
Oxycodone General information
-
Oxygen General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation: (medical gas)
IndicationsSectionMedical gases- Respiratory > Inhalation:
Indications -
Oxytocin General information
SectionUterotonics- Parenteral > General injections > unspecified: 10 IU per mL
Indications -
P-aminosalicylic acid General information
SectionAntituberculosis medicines- Oral > Solid: 500 mg tablet; 4 g granules in sachet
Indications -
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Kaposi sarcoma of unspecified primary site Malignant neoplasms of nasopharynx Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Pancreatic enzymes General information
SectionPancreatic enzymes- Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
Indications -
Paracetamol General information
SectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
- Oral > Solid: 300 to 500 mg
IndicationsSectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 100 mg
Indications -
Paromomycin General information
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
Indications -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial
Indications -
Pegylated interferon alfa (2a) General information
SectionMedicines for hepatitis C > Other antivirals for hepatitis C- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
Indications -
Pegylated interferon alfa (2b) General information
SectionMedicines for hepatitis C > Other antivirals for hepatitis C- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
Indications -
Pembrolizumab General information
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab for Melanoma of skin -
Penicillamine General information
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: 250 mg
SectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 250 mg
Indications -
Pentamidine General information
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection
IndicationsSectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid: 200 mg tablet; 300 mg tablet
Indications -
Permethrin General information
SectionDermatological medicines (topical) > Scabicides and pediculicides- Local > Topical > Lotion: 1%
- Local > Topical > Cream: 5%
Indications -
Pertussis vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Phenobarbital General information
SectionAnticonvulsants/antiepileptics- Oral > Liquid: 15 mg per 5 mL
- Oral > Solid: 15 to 100 mg
- Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium)
Indications -
Phenoxymethylpenicillin General information
SectionAccess group antibiotics- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt) tablet
- Oral > Solid: 250 mg (as potassium salt)
-
Phenytoin General information
SectionAnticonvulsants/antiepileptics- Oral > Liquid: 25 to 30 mg per 5 mL
- Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet
- Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt)
Indications -
Phytomenadione General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
- Oral > Solid: 10 mg tablet
-
Pilocarpine General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
-
Piperacillin + tazobactam General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
-
Platelets General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Plazomicin General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 500 mg per 10 mL (Injection)
-
Pneumococcal vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Podophyllotoxin General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to podophyllum resin for Plantar warts Therapeutic equivalent to podophyllum resin for Anogenital warts -
Podophyllum resin General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 10 to 25%
Indications -
Poliomyelitis vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Polygeline General information
SectionPlasma substitutes- Parenteral > General injections > IV: 3.5% injectable solution
IndicationsTherapeutic equivalent to dextran 70 for Hypovolaemia -
Polymyxin b General information
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 500000 IU in vial powder for injection
-
Potassium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Oral > Liquid: powder for solution
Indications -
Potassium ferric hexacyanoferrate General information
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: Powder for oral administration
-
Potassium iodide General information
SectionAntifungal medicines- Local > Topical > Solution: Saturated solution
IndicationsSectionThyroid hormones and antithyroid medicines- Oral > Solid: 60 mg
Indications -
Potassium permanganate General information
SectionDermatological medicines (topical) > Anti-infective medicines- Local > Topical > Solution: aqueous solution: 1:10 000
-
Povidone iodine General information
SectionAntiseptics- Local > Topical > Solution: 10% (equivalent to 1% available iodine)
Indications -
Pravastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Praziquantel General information
SectionIntestinal anthelminthics- Oral > Solid: 600 mg tablet; 150 mg tablet
- Oral > Solid: 600 mg tablet
SectionAntischistosomals and other antitrematode medicines- Oral > Solid: 600 mg tablet
Indications -
Prednisolone General information
SectionHormones and antihormones- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg
SectionOphthalmological preparations > Anti-inflammatory agents- Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
IndicationsSectionAnti-inflammatory medicines- Local > Rectal > Retention enema:
IndicationsTherapeutic equivalent to hydrocortisone for Crohn disease site Therapeutic equivalent to hydrocortisone for Ulcerative colitisSectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg
-
Primaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
-
Procaine benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
-
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid: 50 mg (as hydrochloride)
Indications -
Progesterone vaginal ring General information
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
-
Proguanil General information
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg tablet (hydrochloride)
Indications -
Propofol General information
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > unspecified: 10 mg per mL; 20 mg per mL
Indications -
Propranolol General information
SectionAntimigraine medicines > For prophylaxis- Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
Indications -
Propylthiouracil General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 mg
Indications -
Prostaglandin e1 General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 0.5 mg per mL in alcohol
Indications -
Prostaglandin e2 General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 1 mg per mL
Indications -
Protamine sulfate General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
-
Pyrantel General information
SectionIntestinal anthelminthics- Oral > Liquid: 50 mg per mL (as embonate or pamoate)
- Oral > Solid: 250 mg chewable tablet (as embonate or pamoate)
Indications -
Pyrazinamide General information
SectionAntituberculosis medicines- Oral > Liquid: 30 mg per mL
- Oral > Solid: 400 mg tablet; 150 mg tablet (dispersible); 150 mg tablet (scored)
Indications -
Pyridostigmine General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
- Oral > Solid: 60 mg (pyridostigmine bromide)
Indications -
Pyridoxine General information
SectionVitamins and minerals- Oral > Solid: 25 mg (hydrochloride)
-
Pyrimethamine General information
SectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid: 25 mg
Indications -
Quinine General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
- Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
Indications -
Rabies vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Raltegravir General information
SectionAntiretrovirals > Integrase inhibitors- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable); 100 mg tablet (chewable)
- Oral > Other: 100 mg granules for oral suspension
-
Ranitidine General information
SectionAntiulcer medicines- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
-
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Red blood cells General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Retinol General information
SectionVitamins and minerals- Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
- Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
- Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
Indications -
Ribavirin General information
SectionOther antivirals- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg
SectionMedicines for hepatitis C > Other antivirals for hepatitis C- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg
Indications -
Riboflavin General information
SectionVitamins and minerals- Oral > Solid: 5 mg
Indications -
Rifabutin General information
SectionAntituberculosis medicines- Oral > Solid: 150 mg
Indications -
Rifampicin General information
SectionAntileprosy medicines- Oral > Solid: 150 mg; 300 mg
IndicationsSectionAntituberculosis medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
Indications -
Rifapentine General information
SectionAntituberculosis medicines- Oral > Solid: 150 mg tablet
Indications -
Risperidone General information
SectionMedicines used in psychotic disorders- Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
-
Ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Liquid: 400 mg per 5 mL
- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
- Oral > Other: 100 mg powder
-
Rituximab General information
SectionTargeted therapies- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
-
Rivaroxaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism -
Rotavirus vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Rubella vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Salbutamol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
- Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
- Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
Indications -
Salicylic acid General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
-
Selenium sulfide General information
SectionDermatological medicines (topical) > Antifungal medicines- Local > Topical > Suspension: 2% detergent-based
Indications -
Senna General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 7.5 mg per 5 mL oral liquid
IndicationsSectionLaxatives- Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
Indications -
Silver sulfadiazine General information
SectionDermatological medicines (topical) > Anti-infective medicines- Local > Topical > Cream: 1%
Indications -
Simvastatin General information
SectionLipid-lowering agents- Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
Indications -
Sodium calcium edetate General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
-
Sodium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
-
Sodium fluoride General information
SectionVitamins and minerals- In any appropriate topical formulation
Indications -
Sodium hydrogen carbonate General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)
Indications -
Sodium nitrite General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule
-
Sodium nitroprusside General information
SectionAntihypertensive medicines- Parenteral > General injections > IV: 50 mg in ampoule powder for infusion
Indications -
Sodium stibogluconate General information
SectionAntileishmaniasis medicines- Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
-
Sodium thiosulfate General information
SectionDermatological medicines (topical) > Antifungal medicines- Local > Topical > Solution: 15%
IndicationsSectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule
-
Sofosbuvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 400 mg tablet
IndicationsTherapeutic equivalent to daclatasvir for Chronic hepatitis C Therapeutic equivalent to glecaprevir + pibrentasvir for Chronic hepatitis C Therapeutic equivalent to sofosbuvir + velpatasvir for Chronic hepatitis C Chronic hepatitis C -
Sofosbuvir + velpatasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 400 mg + 100 mg tablet
IndicationsTherapeutic equivalent to daclatasvir for Chronic hepatitis C Therapeutic equivalent to glecaprevir + pibrentasvir for Chronic hepatitis C Chronic hepatitis C Therapeutic equivalent to sofosbuvir for Chronic hepatitis C -
Spectinomycin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection
-
Spironolactone General information
SectionMedicines used in heart failure- Oral > Solid: 25 mg
Indications -
Streptokinase General information
SectionThrombolytic medicines- Parenteral > General injections > IV: 1.5 million IU in vial powder for injection
Indications -
Streptomycin General information
SectionAntituberculosis medicines- Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial
Indications -
Succimer General information
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: 100 mg
-
Sulfadiazine General information
SectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid: 500 mg
Indications -
Sulfadoxine + pyrimethamine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 500 mg + 25 mg tablet
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Solid: 500 mg + 25 mg tablet
- Oral > Solid: 250 mg + 12.5 mg tablet
Indications -
Sulfamethoxazole + trimethoprim General information
SectionAntipneumocystosis and antitoxoplasmosis medicines- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
IndicationsSectionAccess group antibiotics- Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule
- Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
- Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
-
Sulfasalazine General information
SectionAnti-inflammatory medicines- Oral > Solid: 500 mg
- Local > Rectal > Suppository: 500 mg
- Local > Rectal > Retention enema:
IndicationsSectionDisease-modifying agents used in rheumatoid disorders (DMARDs)- Oral > Solid: 500 mg
Indications -
Suramin sodium General information
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Parenteral > General injections > IV: 1 g in vial
Indications -
Surfactant General information
SectionMedicines administered to the neonate [c]- Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation
Indications -
Suxamethonium General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial
-
Tamoxifen General information
SectionHormones and antihormones- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
-
Telmisartan + amlodipine General information
SectionAntihypertensive medicines- Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg
Indications -
Telmisartan + hydrochlorothiazide General information
SectionAntihypertensive medicines- Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg
Indications -
Tenofovir disoproxil fumarate General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
SectionMedicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)
Indications -
Terbinafine General information
SectionDermatological medicines (topical) > Antifungal medicines- Local > Topical > Cream: 1% terbinafine hydrochloride
- Local > Topical > Ointment: 1% terbinafine hydrochloride
Indications -
Testosterone General information
SectionAndrogens- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
-
Tetanus vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Tetracaine General information
SectionOphthalmological preparations > Local anaesthetics- Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)
Indications -
Tetracycline General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)
-
Thalidomide General information
SectionImmunomodulators- Oral > Solid: 50 mg
Indications -
Thiamine General information
SectionVitamins and minerals- Oral > Solid: 50 mg (hydrochloride)
Indications -
Tick-borne encephalitis vaccine General information
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Timolol General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)
Indications -
Tioguanine General information
SectionCytotoxic medicines- Oral > Solid: 40 mg
Indications -
Tiotropium bromide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > dry powder: 18 µg capsule
- Respiratory > Inhalation > solution: 1.25 µg per actuation; 2.5 µg per actuation
Indications -
Tranexamic acid General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
IndicationsSectionOther medicines administered to the mother- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
Indications -
Trastuzumab General information
SectionTargeted therapies- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
Indications -
Triclabendazole General information
SectionAntischistosomals and other antitrematode medicines- Oral > Solid: 250 mg tablet
Indications -
Tropicamide General information
SectionDiagnostic agents > Ophthalmic medicines- Local > Ophthalmological > Solution (eye drops): 0.5%
Indications -
Tuberculin, purified protein derivative General information
SectionImmunologicals > Diagnostic agents- Parenteral > Locoregional injections > Intradermal:
Indications -
Typhoid vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Ulipristal General information
SectionOral hormonal contraceptives- Oral > Solid: 30 mg tablet (ulipristal acetate)
-
Urea General information
SectionDermatological medicines (topical) > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 10%; 5%
- Local > Topical > Ointment: 10%; 5%
Indications -
Valaciclovir General information
-
Valganciclovir General information
SectionOther antivirals- Oral > Liquid: 50 mg per mL powder for oral solution
- Oral > Solid: 450 mg Tablet
Indications -
Valproic acid General information
SectionAnticonvulsants/antiepileptics- Oral > Liquid: 200 mg per 5 mL (sodium valproate)
- Oral > Solid: 200 mg (sodium valproate) enteric-coated tablet; 500 mg (sodium valproate) enteric-coated tablet; 100 mg (sodium valproate) crushable tablet
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule (sodium valproate); 100 mg per mL in 10 mL ampoule (sodium valproate)
IndicationsSectionMedicines used in bipolar disorders- Oral > Solid: 200 mg enteric-coated (sodium valproate); 500 mg enteric-coated (sodium valproate)
Indications -
Vancomycin General information
SectionWatch group antibiotics- Oral > Solid: 125 mg (as hydrochloride); 250 mg (as hydrochloride)
- Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection
-
Varicella vaccine General information
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
-
Vecuronium General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)
-
Verapamil General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)
- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
IndicationsSectionAntianginal medicines- Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)
Indications -
Vinblastine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
-
Vincristine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
IndicationsKaposi sarcoma of other specified primary sites Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Follicular lymphoma Lymphoid leukaemia, NOS Rhabdomyosarcoma primary site Diffuse large B-cell lymphomas Retinoblastoma Hodgkin lymphoma Burkitt lymphoma including Burkitt leukaemia -
Vinorelbine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
-
Voriconazole General information
SectionAntifungal medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection
- Oral > Liquid: 40 mg per mL powder for oral liquid
- Oral > Solid: 50 mg tablet; 200 mg tablet
-
Warfarin General information
SectionMedicines affecting coagulation- Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)
-
Water for injection General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Miscellaneous- Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule
-
Whole blood General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Xylometazoline General information
SectionEar, nose and throat medicines [c]- Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL
Indications -
Yellow fever vaccine General information
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Zidovudine General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 250 mg capsule; 300 mg tablet
-
Zinc sulfate General information
SectionMedicines for diarrhoea- Oral > Solid: 20 mg
Indications -
Zoledronic acid General information
SectionSupportive medicines- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle